New drug duo tested in fight against Tough-to-Treat cancers
NCT ID NCT06302621
Summary
This early-stage study is testing the safety and initial effectiveness of combining two targeted cancer drugs, pemigatinib and afatinib, in people with advanced solid tumors that have specific genetic changes and have stopped responding to standard treatments. The main goals are to find the highest dose that can be given safely and to see if the combination can shrink tumors, particularly in a type of bile duct cancer. About 70 participants with advanced cancer will receive the drug combination for as long as it helps them and they can tolerate the side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.